134 related articles for article (PubMed ID: 9126144)
1. Problems with current pharmacologic treatment of Parkinson's disease.
Hurtig HI
Exp Neurol; 1997 Mar; 144(1):10-6. PubMed ID: 9126144
[TBL] [Abstract][Full Text] [Related]
2. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
Verhagen Metman L
Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
[TBL] [Abstract][Full Text] [Related]
3. Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Chase TN; Baronti F; Fabbrini G; Heuser IJ; Juncos JL; Mouradian MM
Neurology; 1989 Nov; 39(11 Suppl 2):7-10; discussion 19. PubMed ID: 2685653
[TBL] [Abstract][Full Text] [Related]
4. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
[TBL] [Abstract][Full Text] [Related]
5. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
Jenner P
Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
[TBL] [Abstract][Full Text] [Related]
6. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW
Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
[TBL] [Abstract][Full Text] [Related]
7. The evolution and origin of motor complications in Parkinson's disease.
Obeso JA; Rodriguez-Oroz MC; Chana P; Lera G; Rodriguez M; Olanow CW
Neurology; 2000; 55(11 Suppl 4):S13-20; discussion S21-3. PubMed ID: 11147505
[TBL] [Abstract][Full Text] [Related]
8. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
Tse W
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
[TBL] [Abstract][Full Text] [Related]
9. Levodopa-related motor complications--phenomenology.
Fox SH; Lang AE
Mov Disord; 2008; 23 Suppl 3():S509-14. PubMed ID: 18781677
[TBL] [Abstract][Full Text] [Related]
10. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
11. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
12. [Early treatment of Parkinson's disease with levodopa].
Odekerken VJ; Post B; Verschuur CV; de Bie RM
Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
[TBL] [Abstract][Full Text] [Related]
13. Management of Parkinson's disease a review of current and new therapies.
Mendis T; Suchowersky O; Lang A; Gauthier S
Can J Neurol Sci; 1999 May; 26(2):89-103. PubMed ID: 10352867
[TBL] [Abstract][Full Text] [Related]
14. Levodopa in the treatment of Parkinson's disease: current controversies.
Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
[TBL] [Abstract][Full Text] [Related]
15. Limitations of current Parkinson's disease therapy.
Rascol O; Payoux P; Ory F; Ferreira JJ; Brefel-Courbon C; Montastruc JL
Ann Neurol; 2003; 53 Suppl 3():S3-12; discussion S12-5. PubMed ID: 12666094
[TBL] [Abstract][Full Text] [Related]
16. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
17. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
Baronti F; Ruggieri S; Mouradian MM; Bonamartini A; Bocciarelli P; De Pandis MF; Chase TN; Agnoli A
Riv Neurol; 1991; 61(6):210-4. PubMed ID: 1813972
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological therapy of complicated Parkinson's disease].
Jiménez-Jiménez FJ; Molina JA
Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
[TBL] [Abstract][Full Text] [Related]
19. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
